Income Tax Expense (Benefit) of CERO THERAPEUTICS HOLDINGS, INC. from 30 Sep 2021 to 31 Dec 2023

Taxonomy & unit: us-gaap: USD
Description: Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary: CERO THERAPEUTICS HOLDINGS, INC. annual and quarterly Income Tax Expense (Benefit) in USD history and change rate from 30 Sep 2021 to 31 Dec 2023.
CERO THERAPEUTICS HOLDINGS, INC. Income Tax Expense (Benefit) for the quarter ending 30 Sep 2023 was $25,751, a 57% decline year-over-year.
CERO THERAPEUTICS HOLDINGS, INC. annual Income Tax Expense (Benefit) for 2023 was $94,819, a 84% decline from 2022.
Source SEC data: View on sec.gov

Income Tax Expense (Benefit), Annual (USD)

Income Tax Expense (Benefit), YoY Annual Change (%)

Income Tax Expense (Benefit), Quarterly (USD)

Income Tax Expense (Benefit), YoY Quarterly Change (%)

CERO THERAPEUTICS HOLDINGS, INC. Annual Income Tax Expense (Benefit) (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2023	$94,819	-$504,340	-84%	01 Jan 2023	31 Dec 2023	10-K	02 Apr 2024	2023	FY
2022	$599,159			01 Jan 2022	31 Dec 2022	10-K	02 Apr 2024	2023	FY

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2023	$25,751	-$34,710	-57%	01 Jul 2023	30 Sep 2023	10-Q	09 Nov 2023	2023	Q3
Q2 2023	$44,658			01 Apr 2023	30 Jun 2023	10-Q	14 Aug 2023	2023	Q2
Q3 2022	$60,461	+$60,461		01 Jul 2022	30 Sep 2022	10-Q	09 Nov 2023	2023	Q3
Q3 2021	$0			01 Jul 2021	30 Sep 2021	10-Q	10 Nov 2022	2022	Q3

* An asterisk sign (*) next to the value indicates that the value is likely invalid.